Skip to main content

Branded

  • Pfizer could lose No. 1 global sales ranking to Sanofi next year, report finds

    LONDON — Pfizer soon may lose its distinction of having the highest global sales of any drug company, according to life sciences industry analysis firm EvaluatePharma.

    The next contender for the title is France's Sanofi, which EvaluatePharma said was expected to take the top spot next year and stay there through 2016.

  • J&J submits new FDA application for Nucynta ER

    TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

  • Walgreens offers free testing during National Diabetes Month

    DEERFIELD, Ill. — Select Walgreens across the country will offer free blood-glucose testing during National Diabetes Month this November, Walgreens announced Monday.

  • Obama issues executive order to address drug shortages

    WASHINGTON — President Barack Obama issued an executive order Monday to address the growing problem of drug shortages.

  • Pfizer completes Icagen acquisition

    NEW YORK — Icagen officially is a wholly owned subsidiary of Pfizer.

    As part of the transaction, which first was announced in July, Icagen now will be part of Pfizer’s worldwide research and development organization and also will be integrated into Neusentis, Pfizer’s pain, sensory disorders and regenerative medicine research unit.

    The aggregate transaction value, which includes the value of the shares that already were owned by Pfizer, was about $56 million.

  • FDA approves supplemental new drug application for Abbott's Lupron Depot-PED

    ABBOTT PARK, Ill. — The Food and Drug Administration has approved a supplemental new drug application related to a drug made by Abbott, the company said.

  • Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment

    FOSTER CITY, Calif. — Drug makers Bristol-Myers Squibb and Gilead Sciences announced an agreement to develop and commercialize a fixed-dose combination treatment for patients with HIV.

    The two companies said the drug will combine Bristol's Reyataz (atazanavir sulfate) and Gilead's boosting agent cobicistat, which is designed to increase blood levels of certain HIV medicines to potentially allow for one-pill, once-daily dosing. Gilead is currently studying Reyataz and cobicistat in phase-2 and phase-3 trials.

  • Dynavax releases results of hepatitis B vaccine phase-3 trial

    BERKELEY, Calif. — An experimental vaccine for hepatitis B made by Dynavax Technologies appears to work better in patients with diabetes than current treatments, the company said.

X
This ad will auto-close in 10 seconds